ReviewMolecular biotechnology2001
Cowpea mosaic virus as a vaccine carrier of heterologous antigens.
Review in Molecular biotechnology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 50 citations in OpenAlex.
- Plant Virus Nanoparticles Combat Cancer.Vaccines · 2023Review
- Review
- Feasibility of Cowpea chlorotic mottle virus-like particles as scaffold for epitope presentations.BMC biotechnology · 2015Article
- Production of Hybrid Chimeric PVX Particles Using a Combination of TMV and PVX-Based Expression Vectors.Frontiers in bioengineering and biotechnology · 2015Article
- Virus-mimicking nano-constructs as a contrast agent for near infrared photoacoustic imaging.Nanoscale · 2013Article
- Tobacco mosaic virus as a new carrier for tumor associated carbohydrate antigens.Bioconjugate chemistry · 2012Article
- Article
- Protein nanocapsules containing doxorubicin as a pH-responsive delivery system.Small (Weinheim an der Bergstrasse, Germany) · 2011Article
- Intravital imaging of embryonic and tumor neovasculature using viral nanoparticles.Nature protocols · 2010Article
- Plant-made vaccines for humans and animals.Plant biotechnology journal · 2010Review
- Endothelial targeting of cowpea mosaic virus (CPMV) via surface vimentin.PLoS pathogens · 2009Article
- Cowpea mosaic virus capsid: a promising carrier for the development of carbohydrate based antitumor vaccines.Chemistry (Weinheim an der Bergstrasse, Germany) · 2008Article
- Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells.Chemistry & biology · 2007Article
- Inactivation and purification of cowpea mosaic virus-like particles displaying peptide antigens from Bacillus anthracis.Journal of virological methods · 2007Article
- Interaction between a 54-kilodalton mammalian cell surface protein and cowpea mosaic virus.Journal of virology · 2007Article
- Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo.International journal of nanomedicine · 2007Article
- Viral nanoparticles as tools for intravital vascular imaging.Nature medicine · 2006Article
- Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges.Molecular biotechnology · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The plant virus, cowpea mosaic virus (CPMV), has been developed as an expression and presentation system to display antigenic epitopes derived from a number of vaccine targets including infectious disease agents and tumors. These chimeric virus particles (CVPs) could represent a cost-effective and safe alternative to live replicating virus and bacterial vaccines. A number of CVPs have now been generated and their immunogenicity examined in a number of animal species. This review details the humoral and cellular immune responses generated by these CVPs following both parenteral and mucosal delivery and highlights the potential of CVPs to elicit protective immunity from both viral and bacterial infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.